[ad_1]
Anteris Technologies has announced the launch of its initial public offering in the U.S. The company aims to raise funds to advance the development of its DurAVR transcatheter heart valve technology. The IPO consists of 14.8 million shares of common stock, with an additional 2.22 million shares available to underwriters. Anteris has applied to list its shares on the Nasdaq Global Market under the AVR ticker.
Proceeds from the IPO will support the development of the DurAVR heart valve and the start of a global pivotal study targeting severe aortic stenosis treatment. Any leftover funds will go towards working capital, corporate purposes, and the repayment of convertible note facility obligations.
The DurAVR is a transcatheter heart valve designed to treat aortic stenosis. It uses a single piece of bioengineered tissue shaped to mimic the performance of a healthy human aortic valve. The valve is made using Anteris’ patented anti-calcification tissue technology, Adapt Tissue, which has been clinically used for over a decade.
The DurAVR is delivered through the ComASUR Delivery System, providing controlled deployment and accurate placement with balloon-expandable delivery. The system is designed to achieve precise alignment with the heart’s native commissures for optimal valve positioning.
Overall, Anteris Technologies’ IPO will help fund the development and potential commercialization of its innovative DurAVR transcatheter heart valve technology, which has the potential to improve outcomes for patients with aortic stenosis.
Source
Photo credit www.massdevice.com
